Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFER: Dulaglutide vs Semaglutide Pen Preference
NCT03724981Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Participant Preference Between 2 Injection Devices Based on Global Preference Item at Day 1. Started Oct 2018; status: completed.
Beyond the preview
Go deeper on NCT03724981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724981.